For the quarter ended June 2025, Penumbra (PEN Quick QuotePEN - Free Report) reported revenue of $339.46 million, up 13.4% over the same period last year. EPS came in at $0.86, compared to $0.64 in the year-ago quarter.

The reported revenue represents a surprise of +3.54% over the Zacks Consensus Estimate of $327.85 million. With the consensus EPS estimate being $0.81, the EPS surprise was +6.17%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- International: $78.64 million versus the four-analyst average estimate of $70.83 million. The reported number represents a year-over-year change of -3.2%.
• Revenue- Thrombectomy - United States: $188.53 million compared to the $188.29 million average estimate based on four analysts.
• Geographic Revenue- United States: $260.82 million versus $257.86 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.5% change.
• Revenue- Embolization and Access - United States: $72.29 million versus the four-analyst average estimate of $69.57 million.
• Revenue- Embolization and Access - International: $36.91 million versus $28.67 million estimated by four analysts on average.
• Revenue- Thrombectomy - International: $41.72 million versus $42.16 million estimated by four analysts on average.
• Revenue- Embolization and Access: $109.2 million versus the four-analyst average estimate of $98.24 million. The reported number represents a year-over-year change of +13.9%.
• Revenue- Thrombectomy: $230.26 million versus the four-analyst average estimate of $230.45 million. The reported number represents a year-over-year change of +13.2%.

View all Key Company Metrics for Penumbra here>>>

Shares of Penumbra have returned -10.3% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.